Survodutide (BI 456906) | CAS 2805997-46-8 | Dual Glucagon/GLP-1 Receptor Agonist (Research Use Only) | Knowlux

Product Description

Survodutide, CAS 2805997-46-8, is a synthetic dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist supplied by Knowlux for laboratory research use. It is a long-acting peptide engineered with a fatty acid side chain to extend its half-life and support once-weekly dosing. The molecular formula is C192H289N47O61 and the molecular weight is 4231.63 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Product Parameters

Product Details

1. Overview

Survodutide (BI 456906) is an investigational dual agonist targeting the glucagon receptor and the GLP-1 receptor, designed to replicate the actions of oxyntomodulin, an endogenous hormone that influences body weight and liver health. It is being developed by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), and is not approved for routine clinical use in any jurisdiction. The molecule incorporates a fatty acid side chain that enables albumin binding and once-weekly subcutaneous administration.

2. Mechanism of Action

Survodutide activates both the glucagon receptor and the GLP-1 receptor. The proposed mechanism combines reduced food intake through GLP-1 receptor agonism with glucagon receptor-mediated effects on energy expenditure and hepatic metabolism. Preclinical and clinical data indicate that this dual activity translates into reductions in liver fat content and body weight. In the Phase 3 SYNCHRONIZE-MASLD trial, survodutide 6.0 mg achieved a mean relative reduction in liver fat content of -58.7% versus -9.5% for placebo at week 48, and a mean body weight change of -12.2% versus -1.0%. Gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were the most commonly reported events and occurred predominantly during dose escalation.

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard and impurity studies for dual GCGR/GLP-1R agonist analytical methods

• GCGR and GLP-1R binding and functional assay development

• Formulation development for long-acting injectable peptides

• Metabolic disease model research, including obesity, hepatic lipid metabolism and MASLD studies

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Survodutide is an investigational molecule and is not approved for routine clinical use in any jurisdiction. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.